| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Neuropeptide Y (29-64), amide targets neuropeptide Y receptors, which are G protein-coupled receptors involved in various physiological functions including appetite regulation, circadian rhythms, and anxiety. Neuropeptide Y is a regulatory molecule encoded by a gene mapped to human chromosome 7p15. The peptide fragment is associated with Alzheimer's disease and protects mouse cortical neurons against amyloid toxicity.
|
|---|---|
| ln Vitro |
The findings indicate that human neuropeptide Y shields cortical neurons against the toxicity of Aβ25–35. At 24 and 48 hours, the harmful effects of Aβ25-35 were eliminated by 2 μM NPY. When neurons were pretreated with 1 μM and 0.5 μM Neuropeptide Y (human), the same effects were seen on neuronal survival. In cortical neurons exposed to Aβ35–25, pretreatment with neuropeptide Y (29–64), amide, human (TFA) enhances NGF synthesis, lowers NGF mRNA, and restores NGF release [1].
In vitro, Neuropeptide Y (29-64), amide is used to study the biological activities of NPY fragments. NPY is known to be involved in the regulation of energy balance, memory and learning, and epilepsy. The peptide fragment is associated with Alzheimer's disease and protects mouse cortical neurons against amyloid beta toxicity. |
| ln Vivo |
In vivo, Neuropeptide Y (29-64), amide is associated with Alzheimer's disease and protects mouse cortical neurons against amyloid toxicity. NPY is involved in numerous physiologic processes in the brain, including the regulation of energy balance, memory and learning, and epilepsy. Further in vivo studies are needed to fully characterize the effects of this specific fragment.
|
| Enzyme Assay |
In vitro receptor binding assays for Neuropeptide Y (29-64), amide involve measuring its affinity for neuropeptide Y receptors using radioligand binding techniques. The peptide is incubated with membranes expressing NPY receptors and a radiolabeled NPY analog. These cell-free assays provide quantitative data on the peptide's receptor binding properties.
|
| Cell Assay |
In vitro cellular assays for Neuropeptide Y (29-64), amide are performed using neuronal cell lines or primary neurons. Cells are treated with the peptide, and downstream signaling pathways are assessed. Neuroprotective effects are evaluated by measuring cell viability following exposure to amyloid beta toxicity. These assays characterize the peptide's biological activity.
|
| Animal Protocol |
In vivo animal experimental protocols for Neuropeptide Y (29-64), amide are not extensively documented. As a research peptide, in vivo studies would typically involve administration to animal models to study NPY-related physiological processes such as energy balance, memory, or neurodegeneration. The peptide would be administered via appropriate routes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Neuropeptide Y (29-64), amide have not been systematically characterized. The peptide has a molecular weight of 4271.68 and molecular formula C189H285N55O57S. It is soluble in DMSO. The compound should be stored at -20°C. Further PK studies are needed.
|
| Toxicity/Toxicokinetics |
Toxicological data for Neuropeptide Y (29-64), amide are not extensively reported. As a research-use peptide, its safety profile has not been formally evaluated. The compound is intended for research purposes only. Standard laboratory safety precautions should be followed when handling this peptide.
|
| References | |
| Additional Infomation |
Neuropeptide Y (29-64), amide, human is a 36-amino acid peptide with CAS number 90880-35-6, molecular formula C189H285N55O57S, and molecular weight 4271.68. It is a fragment of human neuropeptide Y encompassing residues 29-64 with an amidated C-terminus. NPY is a neurotransmitter involved in energy balance, memory, learning, and epilepsy. This product is for research use only.
|
| Molecular Formula |
C189H285N55O57S
|
|---|---|
| Molecular Weight |
4271.68454051018
|
| CAS # |
90880-35-6
|
| Related CAS # |
Neuropeptide Y (human) (TFA);[D-Arg25]-Neuropeptide Y (human)
|
| Appearance |
White to off-white solid powder
|
| SMILES |
NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@]([H])(NC(=O)[C@@]([H])(NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@]([H])(NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC([C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC([C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC([C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC([C@@H]1CCCN1C(=O)[C@@H](N[H])CC1C=CC(O)=CC=1)=O)CO)CCCCN)=O)CC(O)=O)CC(=O)N)=O)CCC(O)=O)CC(O)=O)C)=O)C)CCC(O)=O)CC(O)=O)CCSC)C)CCCNC(N)=N)CC1C=CC(O)=CC=1)CC1C=CC(O)=CC=1)CO)C)CC(C)C)CCCNC(N)=N)CC1=CN=CN1)CC1C=CC(O)=CC=1)[C@H](CC)C)CC(=O)N)CC(C)C)[C@H](CC)C)[C@@H](C)O)CCCNC(N)=N)CCC(N)=O)CCCNC(N)=N)CC1C=CC(O)=CC=1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~5.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2341 mL | 1.1705 mL | 2.3410 mL | |
| 5 mM | 0.0468 mL | 0.2341 mL | 0.4682 mL | |
| 10 mM | 0.0234 mL | 0.1170 mL | 0.2341 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
